Brief: AIM Vaccine Sees FY Unaudited Revenue RMB1.25 Billion To RMB1.3 Billion
17/03/2025 02:58
March 17 (Reuters) - AIM Vaccine Co Ltd 6660.HK: SEES UNAUDITED REVENUE RANGING FROM RMB1.25 BILLION TO RMB1.3 BILLION FOR YEAR SEES UNAUDITED NET LOSS RANGING FROM RMB250 MILLION TO RMB290 MILLION FOR YEAR Further company coverage: 6660.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM Vaccine
See all newsBrief: AIM Vaccine Co Submits Application For Human Diploid Cell Rabies Vaccine In China
Brief: AIM Vaccine Says Tibet Bohai To Subscribe 37.4 Million Shares At RMB1.07 Each
Brief: AIM Vaccine Approves Issuance Of Up To 40 Million Domestic Shares
Brief: Aim Vaccine Says Serum-Free Rabies Vaccine Passes Inspection
Brief: AIM Vaccine Updates On 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine